Screening for prostate cancer: Current status of ERSPC and screening-related issues

Recent Results in Cancer Research

Volumn 202, Issue , 2014, Pages 47-51

  Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; GLEASON SCORE; HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SCREENING TEST; FOLLOW UP; METHODOLOGY;

EUROPE; HUMANS; MALE; MASS SCREENING; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE VALUES;

EID: 84958538174     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-45195-9_5     Document Type: Article

References (6)

1. Draisma G et al (2006) Gleason score, age and screening: modelling dedifferentiation in prostate cancer. Int J Cancer 119(10): 2366-2371
2. Heijnsdijk AM et al (2012) Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 367(7): 595-605
3. Schröder FH et al (2012a) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981-990
4. Schröder FH et al (2012b) Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European randomized study of screening for prostate cancer (ERSPC). Eur Urol 62(5): 745-752
5. Zhu X et al (2011) Identifying and characterizing 'escapes'-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam). Int J Cancer 129(12): 2847-2854
6. Zhu X et al (2013) Disease-specific survival of men with screen-detected prostate cancer: comparison of first round versus second round cancers in a European randomized screening trial. EAU, Milan. abstract nr. 5